• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Neutrophil Heterogeneity and its Roles in the Inflammatory Network after Ischemic Stroke
Curr Neuropharmacol. 2022 Jul 6. doi: 10.2174/1570159X20666220706115957. Online ahead of print.ABSTRACTAs the first peripheral immune cells to enter the brain after ischemic stroke, neutrophils are important participants in stroke-related neuroinflammation. Neutrophils are quickly mobilized from the periphery in response to a stroke episode and cross the blood-brain barrier to reach the ischemic brain parenchyma. This process involves the mobilization and activation of neutrophils from peripheral immune organs (including the bone marrow and spleen), their chemotaxis in the peripheral blood, and their infiltration into the ...
Source: Current Neuropharmacology - July 7, 2022 Category: Drugs & Pharmacology Authors: Meizhen Xie Yulei Hao Liangshu Feng Tian Wang Mengyue Yao Hui Li Di Ma Jiachun Feng Source Type: research

Neuroprotective Strategies for Stroke by Natural Products: Advances and Perspectives
Curr Neuropharmacol. 2023 Jul 17. doi: 10.2174/1570159X21666230717144752. Online ahead of print.ABSTRACTCerebral ischemic stroke is a disease with high prevalence and incidence. Its management focuses on rapid reperfusion with intravenous thrombolysis and endovascular thrombectomy. Both therapeutic strategies reduce disability, but the therapy time window is short, and the risk of bleeding is high. Natural products (NPs) have played a key role in drug discovery, especially for cancer and infectious diseases. However, they have made little progress in clinical translation and pose challenges to the treatment of stroke. Rece...
Source: Current Neuropharmacology - July 17, 2023 Category: Drugs & Pharmacology Authors: Aifen Liu Jingyan Hu Tzu-Shao Yeh Chengniu Wang Jilong Tang Xiaohong Huang Bin Chen Liexiang Huangfu Weili Yu Lei Zhang Source Type: research

Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Abstract The relevance of tyrosine kinase inhibitors (TKIs) in the treatment of malignancies has been already defined. Aberrant activation of tyrosine kinase signaling pathways has been causally linked not only to cancers but also to other non-oncological diseases. This review concentrates on the novel plausible usage of this group of drugs in neurological disorders, such as ischemic brain stroke, subarachnoid hemorrhage, Alzheimer's disease, multiple sclerosis. The drugs considered here are representatives of both receptor and non-receptor TKIs. Among them imatinib and masitinib have the broadest spectrum of ther...
Source: Current Neuropharmacology - November 26, 2015 Category: Drugs & Pharmacology Authors: Gagalo I, Rusiecka I, Kocic I Tags: Curr Neuropharmacol Source Type: research

Statins and the brain: more than lipid lowering agents?
CONCLUSION: Even though considerable research studies suggest pivotal functional outcomes induced by statin therapy, additional investigation is required to better determine the pharmacological effectiveness of statins in the brain, and support their clinical use in the management of different neuropathologies. PMID: 28676012 [PubMed - as supplied by publisher]
Source: Current Neuropharmacology - July 3, 2017 Category: Drugs & Pharmacology Authors: Fracassi A, Marangoni M, Rosso P, Pallottini V, Fioramonti M, Siteni S, Segatto M Tags: Curr Neuropharmacol Source Type: research

KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.
This article will briefly review the available compounds (TRAM-34, senicapoc, NS6180), their binding sites and mechanisms of action, and then discuss the potential usefulness of these compounds for the treatment of brain tumors based on their brain penetration and their efficacy in reducing microglia activation in animal models of ischemic stroke and Alzheimer's disease. Senicapoc, which has previously been in Phase III clinical trials, would be available for repurposing, and could be used to quickly translate findings made with other KCa3.1 blocking tool compounds into clinical trials. PMID: 28676010 [PubMed - as supplied by publisher]
Source: Current Neuropharmacology - June 30, 2017 Category: Drugs & Pharmacology Authors: Brown BM, Pressley B, Wulff H Tags: Curr Neuropharmacol Source Type: research

Roles of TRAF6 in central nervous system.
Abstract Tumor necrosis factor receptor-associated factor (TRAF) is an important binding protein of tumor necrosis factor (TNF) superfamily and the toll/IL-1 receptor (TIR) superfamily, which play an important role in innate immunity and acquired immunity. TRAFs family has 7 members (TRAF1-7), and TRAF6 has its special facture and biological function. TRAF6 has two special domains: C-terminal domain and N-terminal domain, which could integrate with multiple kinases and regulate signaling pathway function as E3 ubiquitin ligase. Studies have increasingly found that TRAF6 is closely related to central nervous system...
Source: Current Neuropharmacology - April 11, 2018 Category: Drugs & Pharmacology Authors: Dou Y, Tian X, Zhang J, Wang Z, Chen G Tags: Curr Neuropharmacol Source Type: research

Neuroprotective Potential of Caffeic Acid Phenethyl Ester (CAPE) in CNS Disorders: Mechanistic and Therapeutic Insights
Curr Neuropharmacol. 2021 Jun 8. doi: 10.2174/1570159X19666210608165509. Online ahead of print.ABSTRACTNeurological disorders like Alzheimer's disease (AD), Parkinson's disease (PD), stroke, amyotrophic lateral sclerosis, Huntington's disease (HD), epilepsy, traumatic brain injury (TBI), depression and anxiety are responsible for thousands of deaths worldwide every year. With the increase in life expectancy, there has been a rise in the prevalence of these disorders. Age is one of the major risk factors for these neurological disorders and with the aged population is set to rise to 1.25 billion by 2050. There is a growing ...
Source: Current Neuropharmacology - June 9, 2021 Category: Drugs & Pharmacology Authors: Namrata Pramod Kulkarni Bhupesh Vaidya Acharan Narula Shyam Sunder Sharma Source Type: research

Pages: 1  2